FARMACIA HOSPITALARIA最新文献

{"title":"Evaluación de ecuaciones basadas en creatinina sérica para estimar la tasa de filtración glomerular en pacientes críticos con y sin aclaramiento renal aumentado","authors":"Joan Ramon Roma,&nbsp;Natàlia Arranz-Pasqual,&nbsp;Carla Bastida,&nbsp;Dolors Soy","doi":"10.1016/j.farma.2026.02.018","DOIUrl":"10.1016/j.farma.2026.02.018","url":null,"abstract":"<div><h3>Background</h3><div>Serum creatinine-based equations are commonly used to estimate glomerular filtration rate (eGFR) in critically ill patients, despite not having been specifically developed for this population. This study aimed to assess and compare the performance of three widely used serum creatinine-based equations in this setting.</div></div><div><h3>Methods</h3><div>Observational retrospective study conducted in four intensive care units of a tertiary university hospital. The most commonly used serum creatinine-based equations, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD-4), and Cockcroft-Gault (CG) equations were compared to the creatinine clearance from 24-hour urine collection (CrCl_24h), used as the reference method. Bland and Altman plots, bias and precision were performed to contrast CrCl_24h values with estimated GFR. Bias and its 95% confidence interval were calculated as the mean difference between the eGFR estimated by each equation and the measured CrCl_24h. Precision was reported as one standard deviation of the bias.</div></div><div><h3>Results</h3><div>A total of 261 patients were included. In patients with CrCl_24h between 0–129 mL/min, no significant differences were observed between equations. However, in patients with augmented renal clearance (15.7%), with a mean CrCl_24h of 180 mL/min, there was a statistically significant bias between the CKD-EPI equation (66.4 mL/min/1,73m²) and both the CG and MDRD-4 equations (24.8 mL/min/m² and 29.3 mL/min/1,73 m², respectively; p &lt; 0.01).</div></div><div><h3>Conclusions</h3><div>This study highlights that the most commonly used equations to estimate glomerular filtration rate in critically ill patients have remarkable limitations compared to creatinine clearance from 24-hour urine collection. In critically ill patients with CrCl_24h between 0-129 mL/min, no significant differences were found between the CG, MDRD-4, and CKD-EPI equations. However, for patients with augmented renal clearance, the CG and MDRD-4 equations performed statistically better than the CKD-EPI equation.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 253-259"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Professional profile and expectations of members associated to Pharmaceutical Care in Infectious Diseases group of the Spanish Society of Hospital Pharmacy","authors":"Iván Oterino-Moreira ,&nbsp;Álvaro-Eloy Monje-López ,&nbsp;Beatriz Mejuto ,&nbsp;Alba Pau-Parra ,&nbsp;Leonor Periañez-Parraga ,&nbsp;Sonia Luque","doi":"10.1016/j.farma.2026.02.004","DOIUrl":"10.1016/j.farma.2026.02.004","url":null,"abstract":"<div><h3>Background</h3><div>The Pharmaceutical Care in Infectious Diseases Group (AFinf) is composed of a coordinating group of 11 pharmacists, 1 fellow, 1 resident pharmacist intern, 4 senior consultants and 221 associate members (July 2025). The aim is to understand and describe the profile of the members as a basis for defining future strategic lines to improve their participation.</div></div><div><h3>Methods</h3><div>An online survey was distributed to all AFinf group members, including questions about their professional activity, expectations and potential contributions to the group.</div></div><div><h3>Results</h3><div>The 41.7% of associated professionals participated in the survey. The median length of experience in the area of infectious diseases was 5 years (RIC 2–10). Antimicrobial stewardship programmes represented the main area of expertise (73.9%; 95% CI: 63.2–84.5), followed by pharmacokinetic monitoring (16.9%; 95% CI: 7.8–26.0). The priorities of the adherents were to receive training and education (52.3%; 95% CI: 40.2–64.5%) as well as the need to share doubts and experiences (27.7%; 95% CI: 16.8–38.6). Among the respondents, 50.0% (95% CI: 39.0-61.0) consider that they could contribute ideas and experiences, while 31.3% (95% CI: 21.1–41.4) research/collaborate on projects and 18.7% (95% CI: 10.2–27.3) participate in teaching and other group activities.</div></div><div><h3>Conclusion</h3><div>This study has allowed us to better understand the professional profile of pharmacists who are members of the AFinf group and to analyze their concerns and possible contributions.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T260-T264"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacologic and pharmacokinetic factors in blood donation: A risk-based deferral framework proposal","authors":"Roberto Lozano,&nbsp;María-Esther Franco,&nbsp;Carina Bona","doi":"10.1016/j.farma.2025.12.003","DOIUrl":"10.1016/j.farma.2025.12.003","url":null,"abstract":"<div><h3>Objective</h3><div>The presence of residual medications in blood donors can pose a risk to transfusion recipients, especially when drugs remain in plasma at clinically relevant levels. Current deferral recommendations for medicated donors are often generalized and lack pharmacokinetic rigor. This study aims to propose a pharmacologically and pharmacokinetically informed framework for assessing donor eligibility based on drug characteristics.</div></div><div><h3>Method</h3><div>A structured literature review was conducted to evaluate key pharmacokinetic variables affecting drug persistence in blood, including half-life (<em>t</em>_½), time to maximum plasma concentration (<em>t</em>_max), maximum plasma concentration (<em>C</em>_max), and elimination pathways. Medications were stratified into five risk categories according to their pharmacological profile, systemic exposure, and clinical implications. Corresponding deferral periods were assigned to each category. The framework also considers the type of blood component being donated (e.g., plasma-rich vs. cellular products).</div></div><div><h3>Results</h3><div>Medications with long half-lives, genotoxic effects, or antiplatelet activity pose higher transfusion risks and require extended deferral periods. Conversely, drugs with minimal systemic absorption, low plasma bioavailability, or that serve as physiological replacements pose minimal risk and may not warrant deferral. The proposed model aligns deferral recommendations with drug clearance data and product-specific plasma exposure.</div></div><div><h3>Conclusions</h3><div>A pharmacokinetic approach to donor eligibility enhances transfusion safety and supports evidence-based deferral guidelines. Pharmacists and clinicians can collaborate to assess medication risk profiles and optimize donor selection. This model can reduce unnecessary deferrals and maintain blood supply integrity while protecting recipients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 279-284"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adequacy of three-compartment parenteral nutrition bags to current European guidelines for adults: a simulation study","authors":"Marta de Antonio-Cuscó,&nbsp;Agustí Albalat-Torres,&nbsp;Javier Mateu-de Antonio","doi":"10.1016/j.farma.2026.01.001","DOIUrl":"10.1016/j.farma.2026.01.001","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of three-compartment parenteral nutrition bags (3CPNBs) has widely expanded due to their potential time- and cost-saving advantages compared to hospital-compounded parenteral nutrition bags (HCPNBs). However, there is limited evidence of commercial 3CPNBs to adequately meet current nutritional guidelines.</div></div><div><h3>Objectives</h3><div>This study assessed the nutritional adequacy of all commercial 3CPNBs available in Spain, according to current European guidelines, across four clinical scenarios for adult patients.</div></div><div><h3>Methods</h3><div>A simulation-based study was performed to evaluate the protein and caloric content of 3CPNBs commercially available in Spain. Four clinical scenarios were defined: early and late phases of intensive care (I1 and I2), surgical (Q), and medical (M) inpatients. Two sub-analyses were conducted: a 3CNPB-centered assessment of each formulation's theoretical adequacy for each scenario, and a patient-centered analysis involving 1000 simulated adult patients per scenario (total: 4000 simulations). Patients' weight was computer generated reflecting the published Spanish adult-population values (tested by the Anderson-Darling test and one-sample t-test). Nutritional requirements were calculated using ESPEN guidelines, and adequacy was defined as meeting protein and caloric targets within ±<!--> <!-->5% range. 3CPNBs were further screened for guideline-concordant composition.</div></div><div><h3>Results</h3><div>A total of 50 commercial 3CPNBs were identified, but 15 bags (30.0%) were excluded based on predefined criteria. Then, 35 were included in the study<strong>.</strong> While 51.4% formulations met adequacy criteria across all scenarios, 34.3% were suitable for only one, and 8.6% were unsuitable for any scenario. More than half (57.1%) failed to cover even 10% of patients in any scenario. ICU scenarios, I1 and I2, showed the lowest coverage, with only around 30% of patients with an appropriate 3CPNBs. Many weight strata showed less than 50% coverage depending on the scenario. In the 64–81,99 kg strata, around the population mean, 45.9% lacked an appropriate 3CPNBs across all scenarios.</div></div><div><h3>Conclusions</h3><div>Substantial variability existed in the adequacy of commercial 3CPNBs to ESPEN guidelines. Many formulations failed to meet the criteria or were not usable across all scenarios. Many patients with body weight around population mean had no adequate 3CPNBs. These findings supported the need for critical evaluation of 3CPNBs and still place HCPNBs as a flexible alternative, especially in complex and critically ill populations.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 232-239"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147311141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carga anticolinérgica y su relación con el deterioro cognitivo en una unidad neuropsiquiátrica","authors":"María Ruiz-Julián,&nbsp;Gerard Piñol-Ripoll","doi":"10.1016/j.farma.2026.02.006","DOIUrl":"10.1016/j.farma.2026.02.006","url":null,"abstract":"<div><h3>Background</h3><div>The use of drugs with anticholinergic activity is widespread and appears to be associated with an increased risk of cognitive impairment. We evaluated the prevalence of anticholinergic prescriptions in a neuropsychiatric unit, the anticholinergic burden and its relationship with cognitive impairment.</div></div><div><h3>Methods</h3><div>A cross-sectional observational study was conducted with 135 patients. Sociodemographic data, substance use, medical and psychiatric diagnoses, presence of cognitive impairment, and Mini-Mental State Examination (MMSE) score were collected. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden Scale (ACB) and a composite index of 14 scales, considering a high anticholinergic burden ≥<!--> <!-->3 points. Descriptive analysis, the chi-squared test, Student's <em>t</em>-test, Pearson's correlation coefficient, and multiple lineal regression models adjusted for confounding factors were performed, with <em>p</em> &lt; 0.05 for statistical significance.</div></div><div><h3>Results</h3><div>The mean number of anticholinergics per patient was 4.1 ± 1.7. According to the ACB, the mean burden was 4.8 ± 2.5. The burden was higher in patients with cognitive impairment (<em>t</em> = −<!--> <!-->2.38; <em>p</em> = 0.019). Among those exposed to high burden, 71.7% presented impairment vs. 51.7% exposed to low-moderate burden (<em>χ</em>² = 4.13; <em>p</em> = 0.042; OR = 2.36). With the 14-scale composite, the mean burden was 5.9 ± 2.8. A higher prevalence of impairment was observed in high burden (70% vs 46.7%), although this was not significant (<em>χ</em>² = 3.30; <em>p</em> = 0.069; OR = 2.36). The correlation between ACB burden and MMSE was negative and significant (<em>r</em> = −0.178; <em>p</em> = 0.039), whereas with the composite index, the correlation between total burden and MMSE was not significant (<em>r</em> = −<!--> <!-->0.092; <em>p</em> = 0.289). ACB burden was also associated with a lower MMSE score in the model adjusted for sex and age (<em>B</em> = −0.27; <em>p</em> = 0.047), losing significance after controlling for education and comorbidities (<em>B</em> = −0.24; <em>p</em> = 0.072). The anticholinergic burden estimated with multiple scales showed non-significant coefficients.</div></div><div><h3>Conclusion</h3><div>High anticholinergic consumption and burden are observed in patients with neuropsychiatric disorders, especially those with cognitive impairment. A negative correlation was detected between scores on the ACB scale and the MMSE. The findings confirm that, despite the known negative effect of anticholinergics on cognition, their prescription remains very high in populations at high risk of cognitive impairment.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 247-252"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Application of the Basel Statements self-assessment questionnaire in eight hospitals in Latin America","authors":"Esteban Zavaleta-Monestel,&nbsp;Arturo Villalobos-Madriz,&nbsp;Abigail Fallas-Mora,&nbsp;Ernesto Martínez-Vargas,&nbsp;Amil Munich-Calvo,&nbsp;Vania Teixeira,&nbsp;Silvestre Dalmaso-Neto,&nbsp;César Sánchez,&nbsp;Jorge Morales-Vallespín,&nbsp;Antonella Milano-Gil,&nbsp;Dadier Arroyo-Monterroza,&nbsp;Gladys Delgado-Pérez,&nbsp;Michael Stepanovic,&nbsp;Stephen Eckel,&nbsp;Marianne Ivey","doi":"10.1016/j.farma.2026.02.016","DOIUrl":"10.1016/j.farma.2026.02.016","url":null,"abstract":"<div><div>Objective: The standardization of hospital pharmacy practice remains a challenge in Latin America due to the heterogeneity of healthcare systems. The Basel Statements, developed by the International Pharmaceutical Federation, provide guidelines aimed at improving patient safety and medication management; however, their implementation across the region is inconsistent.</div><div>To evaluate the application of the Basel Statements Self-Assessment Questionnaire in hospitals across Latin America and identify priority areas for improvement.</div></div><div><h3>Method</h3><div>A multicenter study was conducted in eight hospitals from eight countries. A 33-item questionnaire based on the Basel Statements was electronically distributed to clinical and hospital pharmacists. A descriptive analysis was performed.</div></div><div><h3>Results</h3><div>Only 25% of hospitals reported effective integration of pharmacists into clinical decision-making. Fewer than one-third had adequate medication traceability systems. Additionally, only 37.5% reported having regulations for the use of dietary supplements. Lack of standardization in medication storage and administration was also observed, increasing the risk of medication errors.</div></div><div><h3>Conclusions</h3><div>Implementation of the Basel Statements in Latin America is heterogeneous and requires targeted interventions. Strengthening pharmacists' involvement in multidisciplinary teams, improving traceability systems, and developing stronger regulations to support the safe use of medications are essential steps to enhance patient safety in the region.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T217-T224"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Consideraciones farmacológicas y farmacocinéticas para la donación de sangre: propuesta de un marco de aplazamiento basado en el riesgo","authors":"Roberto Lozano,&nbsp;María-Esther Franco,&nbsp;Carina Bona","doi":"10.1016/j.farma.2026.03.003","DOIUrl":"10.1016/j.farma.2026.03.003","url":null,"abstract":"<div><h3>Objective</h3><div>The presence of residual medications in blood donors can pose a risk to transfusion recipients, especially when drugs remain in plasma at clinically relevant levels. Current deferral recommendations for medicated donors are often generalized and lack pharmacokinetic rigor. This study aims to propose a pharmacologically and pharmacokinetically informed framework for assessing donor eligibility based on drug characteristics.</div></div><div><h3>Method</h3><div>A structured literature review was conducted to evaluate key pharmacokinetic variables affecting drug persistence in blood, including half-life (<em>t</em>_½), time to maximum plasma concentration (<em>t</em>_max), maximum plasma concentration (<em>C</em>_max), and elimination pathways. Medications were stratified into five risk categories according to their pharmacological profile, systemic exposure, and clinical implications. Corresponding deferral periods were assigned to each category. The framework also considers the type of blood component being donated (e.g., plasma-rich vs. cellular products).</div></div><div><h3>Results</h3><div>Medications with long half-lives, genotoxic effects, or antiplatelet activity pose higher transfusion risks and require extended deferral periods. Conversely, drugs with minimal systemic absorption, low plasma bioavailability, or that serve as physiological replacements pose minimal risk and may not warrant deferral. The proposed model aligns deferral recommendations with drug clearance data and product-specific plasma exposure.</div></div><div><h3>Conclusions</h3><div>A pharmacokinetic approach to donor eligibility enhances transfusion safety and supports evidence-based deferral guidelines. Pharmacists and clinicians can collaborate to assess medication risk profiles and optimize donor selection. This model can reduce unnecessary deferrals and maintain blood supply integrity while protecting recipients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T279-T284"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer.","authors":"Maria Susana Fortes-Gonzalez, Silvia Vazquez-Blanco, Leticia Herrero-Poch, Lucia Santome-Couto, Ana Cristina Cercos-Lleti","doi":"10.1016/j.farma.2026.05.002","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.002","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess whether immune-related adverse events (irAE) act as predictive biomarkers of response to immune checkpoint inhibitors in non-small-cell lung cancer in real-life practice.</p><p><strong>Methods: </strong>Retrospective observational study in a third-level hospital.</p><p><strong>Inclusion criteria: </strong>adult patients with locally advanced or metastatic non-small-cell lung cancer treated with nivolumab, pembrolizumab or atezolizumab following platinum.</p><p><strong>Primary endpoint: </strong>association between ≥2 irAE and progression free survival (PFS) and overall survival (OS). Secondary endpoints: PFS, OS, overall response rate defined as the percentage of patients who achieve partial response or complete response, disease control rate and adverse events graded according to the Common Terminology Criteria for Adverse Events v5. Statistical analysis was performed using SPSS v23.</p><p><strong>Results: </strong>Fifty-seven patients treated with nivolumab (n = 25) pembrolizumab (n = 11) or atezolizumab (n = 21) were included. Median age was 62 (31-83) years and 81% had stage IV. Median PFS was 7.8 months (95% CI: 4.3-11.3) and OS was 13.4 months (95% CI: 5.8-20.9). Overall response rate and disease control rate were 28.1% and 59.6% respectively. irAEs occurred in 44% of patients, most frequently arthralgia, myalgia, and transaminase elevation. Grade 3 irAEs included: 3 cases of colitis, 2 pneumonitis, 1 hepatitis, 1 cutaneous toxicity, and 1 adrenal insufficiency. Survival was significantly longer in patients with ≥2 irAEs compared to those with <2: OS 28.4 vs 11.9 months (p = 0.025) and PFS 24.5 vs 5.2 months (p = 0.013).</p><p><strong>Conclusions: </strong>Patients experiencing 2 or more irAEs showed significantly improved survival, supporting the role of irAEs as potential biomarkers of response to immunotherapy in non-small-cell lung cancer.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Computerized gravimetric control of parenteral analgesic admixtures: A retrospective quality improvement study.","authors":"Sandra Caíña-López, María Carmen Dávila-Pousa","doi":"10.1016/j.farma.2026.06.003","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.003","url":null,"abstract":"<p><strong>Objective: </strong>Postoperative pain and labor pain are among the most prevalent and intense types of acute pain. Their effective management often requires the administration of parenteral analgesic mixtures combining opioids with local anesthetics. Since no ready-to-use commercial formulations are available and given the complexity and risk of error in their preparation, the Spanish Guide to Good Medication Preparation Practices in Hospital Pharmacy Services recommends their centralized compounding in clean rooms within the pharmacy department. The aim of this study is to describe the implementation experience of a computerized gravimetric control system for stock-prepared analgesic formulations and to assess its reliability and usefulness.</p><p><strong>Method: </strong>A retrospective observational study was conducted including all analgesic units prepared in the Pharmacy Department between July 2024 and April 2025. Gravimetric control was performed using an electronic balance integrated into the Pharmasuite® software, which automatically calculated the concordance between theoretical and actual weight, generating alerts in case of deviations. Primary acceptance limits were set at ±1.5-1.7% depending on the formulation, based on previous experience and the consistency observed in earlier batches. A total of seven different formulations were analyzed.</p><p><strong>Results: </strong>During the study period, 1,460 units were prepared, corresponding to 238 batches. Five out of the seven formulations achieved 100% compliance with the acceptance limit. In the remaining formulations, the proportion of non-compliant units was below 1%. The mean relative standard deviation ranged from 0.189% to 0.338%, always below 0.5%, indicating high reproducibility. The mean actual weight was very close to the theoretical weight in all formulations. Units falling outside the acceptance range were individually discarded, and no complete batch had to be rejected.</p><p><strong>Conclusions: </strong>The implementation of computerized gravimetric control in the compounding of analgesic formulations proved to be an effective and safe strategy to ensure accuracy, detect errors, and reinforce traceability. The experience described represents a quality improvement tool that may be extrapolated to other centers.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depression, stress and medication adherence in patients with type 2 diabetes: A crosssectional study in Mexico.","authors":"Fátima Del Carmen Portillo-Robledo, Marco Antonio León-Mazón, Laura Ávila-Jiménez, Christian Díaz de León-Castañeda, Cairo David Toledano-Jaimes","doi":"10.1016/j.farma.2026.05.005","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.005","url":null,"abstract":"<p><strong>Objective: </strong>To describe the level of adherence to pharmacological treatment and explore, using a bivariate analysis, its unadjusted association with mental health variables (depression and stress) in patients with type 2.</p><p><strong>Method: </strong>A cross-sectional study was conducted with 326 patients with T2D and beneficiaries of a multidisciplinary center of a social security institution in Morelos, Mexico. Sociodemographic, clinical, and mental health variables such as stress and depression were evaluated, in addition to adherence to pharmacological treatment in patients with T2D, using instruments with evidence of validity and reliability. Bivariate statistical analysis was used to evaluate the association between the variables of interest and pharmacological adherence.</p><p><strong>Results: </strong>A statistically significant association was found between pharmacological adherence with depression (χ² = 7.3, p = 0.01; OR = 0.28, p = 0.01), and with depression and stress as concomitance (OR = 0.18, p = 0.02). No statistically significant associations were found with sociodemographic factors.</p><p><strong>Conclusions: </strong>In this cross-sectional study, a bivariate association was observed between depression-and its co-occurrence with stress-and pharmacological adherence. These findings should be interpreted with caution and require confirmation through studies with adjusted analyses.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}